Discover
INTS
Intensity Therapeutics, Inc.
4.15
2 x 2.96
2 x 5.37
bid
ask
+
0.05
1.22%
2 @ 04:00 PM
4.00 -0.15 (3.61%)
| Ytd | -59.51% | |
| 1y | -46.10% |
4.13
day range
4.20
3.51
52 week range
43.50
| Open | 4.15 | Prev Close | 4.10 | Low | 4.13 | High | 4.20 | Mkt Cap | 11.22M |
| Vol | 59.63K | Avg Vol | 38.66K | EPS | -4.01 | P/E | N/A | Forward P/E | -1.66 |
| Beta | N/A | Short Ratio | 3.05 | Inst. Own | 12.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 4.50 | 200-d Avg | 7.58 | 1yr Est | 10.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.27 | -0.25 | 0.02 | 7.41% |
| 2024-08-08 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-08-08 | 2024-06 | 0 | -0.36 | N/A | N/A |
| 2024-03-14 | 2023-12 | 0 | N/A | N/A | N/A |
| 2023-11-13 | 2023-09 | 0 | -0.17 | N/A | N/A |
| 2023-11-13 | 2023-09 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-31 | HC Wainwright & Co. | Upgrade | Buy | |
| 2024-07-11 | Benchmark | Upgrade | Speculative Buy | Speculative Buy |
| 2024-05-16 | Benchmark | Upgrade | Speculative Buy | Speculative Buy |
| 2024-03-21 | Benchmark | Upgrade | Speculative Buy | Speculative Buy |
| 2023-11-14 | Benchmark | Upgrade | Speculative Buy | Speculative Buy |
Profile
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-04 | WESOLOWSKI JOHN CPA | Officer | 6.69K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Sapient Capital LLC | 1.01M | 1.98M | 6.69% |
| 2024-09-29 | Vanguard Group Inc | 208.89K | 408.85K | 1.38% |
| 2024-09-29 | Brown Advisory Inc. | 148.11K | 289.89K | 0.98% |
| 2024-09-29 | Geode Capital Management, LLC | 64.35K | 125.95K | 0.43% |
| 2024-09-29 | Sigma Planning Corp | 47.74K | 93.45K | 0.32% |
| 2024-09-29 | Mesirow Financial Investment Management, Inc. | 44.18K | 86.47K | 0.29% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 168.30K | 329.41K | 1.11% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 40.59K | 79.44K | 0.27% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 34.52K | 67.57K | 0.23% |
| 2024-10-30 | iShares Micro Cap ETF | 20.12K | 39.39K | 0.13% |
| 2024-10-30 | Fidelity Total Market Index Fund | 9.42K | 18.44K | 0.06% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 8.14K | 15.93K | 0.05% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2026-02-19 |